[grow_thumb image=”https://telecareaware.com/wp-content/uploads/2014/07/Baby_with_Biostamp.png” thumb_width=”180″ /][grow_thumb image=”https://telecareaware.com/wp-content/uploads/2014/07/MC10_Biostamp-small.jpg” thumb_width=”150″ /]
Perhaps we should be adding to our sidebar lexicon ‘conformal electronics’. Boston-based wearable health technology developer
MC10 is partnering with Brussels-based biopharmaceutical company
UCB S.A. to develop MC10’s
Biostamp platform for treating those with severe neurological disorders. MC10 developed a seamless, disposable sensing sticker with thin film batteries (right above) which is currently in use in the
Reebok Checklight to determine sports-related concussion risk [
TTA 16 May, “Brain Games”] and in beta for infant temperature sensing (left above). It seems clear from the announcement today and further remarks (see below) that the objective is not drug delivery, but for patient monitoring and disease management. MC10 commercializes
John Rogers’ work in stretchable sensor patches and batteries [
TTA 10 April]. The Biostamp does not have FDA approval but the partnership may be a way to fast-track CE approval.
MC10 release, Fast Company (also reviews
Proteus, Corventis, Given Imaging),
Mobihealthnews with comments from Ben Schlatka, MC10 cofounder.
Most Recent Comments